Unveiling the complex interplay: Microbiome and neurological disorders

Ruffin Jeanine^*
*Correspondence: Ruffin Jeanine, Department of Antimicrobial Resistance, University of Lille, Lille, France, Email:

Received: 28-Feb-2024, Manuscript No. AJMR-24-130302; Editor assigned: 01-Mar-2024, Pre QC No. AJMR-24-130302 (PQ); Reviewed: 18-Mar-2024, QC No. AJMR-24-130302; Revised: 26-Mar-2024, Manuscript No. AJMR-24-130302 (R); Published: 02-Apr-2024

Description

The human microbiome, a diverse community of microorganisms residing in and on our bodies, has garnered increasing attention for its profound influence on health and disease. While much of the focus initially revolved around its role in gastrointestinal health and immune function, emerging research has unveiled its intricate connections with neurological disorders (Akujobi et al., 2008). This symbiotic relationship between the microbiome and the brain has sparked a new frontier in neuroscience, offering insights into the pathogenesis, progression, and potential therapeutic avenues for various neurological conditions (Berri et al., 2015).

Understanding the microbiome

The microbiome comprises a vast array of bacteria, viruses, fungi, and other microorganisms inhabiting different niches of the human body, with the gut microbiota being the most extensively studied (Brooks et al., 2005). This dynamic ecosystem not only aids in digestion and nutrient absorption but also plays a pivotal role in modulating immune responses, synthesizing essential compounds, and influencing neurotransmitter pathways (SFM Antibiogram Committee., 2003).

Microbiome-brain axis

The bidirectional communication between the gut microbiota and the central nervous system, known as the microbiomegut- brain axis, forms the foundation for understanding their influence on neurological function. Through intricate signaling mechanisms involving neural, hormonal, and immune pathways, the microbiome can impact brain development, behavior, cognition, and even mood regulation.

Implications in neurological disorders

Mounting evidence suggests that alterations in the composition and function of the microbiome may contribute to the pathogenesis of various neurological disorders. Conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, autism spectrum disorders, and depression have been linked to dysbiosis, characterized by microbial imbalances or disruptions in the gut-brain axis.

Mechanisms of influence

Several mechanisms underlie the impact of the microbiome on neurological function. These include the production of neuroactive compounds (e.g., neurotransmitters, short-chain fatty acids), modulation of the immune response, regulation of inflammation, maintenance of the blood-brain barrier integrity, and involvement in the production of metabolites crucial for neuronal health (Corrégé, 2013).

Alzheimer’s disease and parkinson’s disease

In Alzheimer’s disease, alterations in the gut microbiota composition and increased intestinal permeability may contribute to neuroinflammation, amyloid-beta accumulation, and cognitive decline (Dadié et al., 2000). Similarly, in Parkinson’s disease, dysbiosis has been implicated in alphasynuclein aggregation, neuroinflammation, and the progression of motor symptoms (Dadié A et al., 2014).

Multiple sclerosis and autism spectrum disorders

Studies have revealed distinct microbiome signatures in individuals with multiple sclerosis, suggesting a potential role in immune dysregulation and demyelination (Dadié A et al., 2010). Similarly, alterations in the gut microbiota composition have been observed in individuals with autism spectrum disorders, with implications for behavior, social interaction, and cognitive function (Fairbrother et al., 2006).

Depression and anxiety

The gut-brain axis also influences mental health, with dysbiosis linked to mood disorders such as depression and anxiety (Brossette SE et al., 2008). The production of neurotransmitters like serotonin and Gamma-Aminobutyric Acid (GABA) by gut bacteria, along with the modulation of inflammatory pathways, highlights the intricate interplay between the microbiome and emotional well-being.

Therapeutic implications

Understanding the microbiome’s role in neurological disorders holds promise for the development of novel therapeutic strategies. Probiotics, prebiotics, dietary interventions, fecal microbiota transplantation, and pharmacological agents targeting the gut microbiota are being explored as potential avenues to modulate microbial composition and improve neurological outcomes.

Conclusion

The burgeoning field of microbiome research is reshaping our understanding of neurological disorders, emphasizing the interconnectedness of the gut and the brain. By elucidating the complex interplay between the microbiome and neurological function, we may uncover new diagnostic biomarkers and therapeutic targets, paving the way for personalized interventions and improved patient outcomes.

References

1. Akujobi CO, Ogbulie JN, Umeh SI, Abanno NU (2008). Antibiotic-resistant Escherichia coli in a government piggery farm in Owerri, Nigeria. Int. J. Biol. Chem. Sci. 2:363-367.

   [Crossref] [Google Scholar].

2. Berri M, Slugocki M, Olivier M, Holbert S, Helloin E, Jacques I, Salmon CPN, et al (2015). L’ activité antibactérienne et immuno modulatrice d’un extrait d’algue verte riche en polysaccharides sulfatés. Journ. Rech. Porc. 47:309-310.

   [Google Scholar].

3. Brooks JT, Sowers EG, Wells JG, Greene KD, Griffin PM, Hoekstra RM, Strockbine NA (2005). Non-O157 Shiga toxin-producing Escherichia coli infections in the United States 1983-2002. J. Infect. Dis. 192:1422-1429.

   [Crossref] [Google Scholar] [PubMed].

4. SFM Antibiogram Committee (2003). Comité de l'Antibiogramme de la Société Française de Microbiologie report 2003. Int J Antimicrob Agents. 21(4):364-391.

   [Google Scholar] [PubMed].

5. Corrégé I (2013). Immunité des porcelets: importance du colostrum. Tech. Porc. 9:41-43.
6. Dadié A, Karou TG, Faye-Kette HY (2000). Isolement d’agents pathogènes entériques en Côte d’Ivoire: Escherichia coli O157:H7 et E. coli entéro-aggrégant. Bull. Soc. Pathol. Exot. 93:95-96.

   [Google Scholar] [PubMed].

7. Dadié A, Kouassi N, Dako E, Dje M, Dosso M (2014). Virulence, serotype and phylogenetic groups of diarrhoeagenic Escherichia coli isolated during digestive infections in Abidjan, Côte d’Ivoire. Afr. J. Biotechnol. 13:998-1008.

   [Crossref] [Google Scholar].

8. Dadié A, Nzebo D, Guessennd N, Dako E, Dosso M (2010). Prevalence of enteropathogenic Escherichia coli in unpasteurized milk produced in Abidjan, Côte d'Ivoire. J. Biol. Chem. Sci. 4:11-18.

   [Crossref] [Google Scholar].

9. Fairbrother JM, Gyles CL (2006). Escherichia coli infections. Diseases of Swine. Iowa state University.  9:639-674.
10. Brossette SE, Hymel PA (2008). Data mining and infection control. Clin Lab Med. 28:119–126.

    [Crossref] [Google Scholar] [PubMed].